ArticleMolecular and clinical oncology2022
Application of PD-L1 blockade in refractory histiocytic sarcoma: A case report.
Article in Molecular and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Durable Response in Histiocytic Sarcoma After Allogeneic Stem Cell Transplantation: A Case Report.Hematology reports · 2025Article
- Histiocytic Sarcoma: A Review and Update.International journal of molecular sciences · 2025Review
- Uncommon but intriguing: A pediatric primary histiocytic sarcoma case-Clinical insights and literature review.Radiology case reports · 2025Article
- Favorable response to nivolumab combined with radiotherapy for retroperitoneal leiomyosarcoma.International cancer conference journal · 2025Article
- Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France.Blood advances · 2025Article
- Langerhans Cell Histiocytosis and Other Histiocytic Lesions.Head and neck pathology · 2025Review
- BRAF V600E mutation and high expression of PD-L1 in Rosai-Dorfman disease: case report and review of the literature.Journal of hematopathology · 2024Review
- Long-Term Remission with Novel Combined Immune-Targeted Treatment for Histiocytic Sarcoma Accompanied by Follicular Lymphoma: Case Report and Literature Review.International journal of molecular sciences · 2024Review
- Primary pulmonary histiocytic sarcoma with high PD-L1 expression benefited from immunotherapy: A case report and bioinformatic analysis.The clinical respiratory journal · 2024Article
- Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report.Annals of medicine and surgery (2012) · 2023Article
- Pembrolizumab Combined With GDP Regimen Inducing Sustained Remission in Histiocytic Sarcoma: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histiocytic sarcoma (HS) is a rare hematological malignancy, which exhibits morphological and immunophenotypic features of histiocytes. A standard therapy for HS has not yet been established due to its rareness; therefore, disease control is not always possible. A multimodal treatment strategy has been suggested for HS. The present study reported on a case of a 43-year-old female patient who complained of left femoral pain, which was caused by left femoral bone mass. A biopsy of their left femoral bone tumor revealed that the patient had HS. Their sarcoma was localized in the femoral bone and was not considered to be curable, due to local infiltration of the bone tumor beyond the periosteum. The patient then underwent two types of HS-specific chemotherapy; however, both regimens were ineffective. As a result, they underwent radiation therapy at the sites of progressive disease. Because the HS cells of the patient expressed PD-L1, they were treated with nivolumab (240 mg/body, biweekly) for residual diseases in the right occipital bone, multiple lung nodules, intrapelvic right lymph node and primary site. Nivolumab treatment resulted in a complete response at all sites, with the exception of the primary site, which was confirmed by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.